Physician profile
Gaurav Bhalla
NPI 1457616120
$11,870.92
in general payments reported to CMS, 2019-2025
48 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,949 · 2020: $1,241 · 2021: $1,621 · 2022: $1,706 · 2023: $1,565 · 2024: $1,157 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,353.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,426.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $1,267.72 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $1,006.57 | 2019-2025 | Tepezza, Repatha, Evenity |
| Abbvie INC. | $903.24 | 2019-2025 | Synthroid |
| Lilly USA, LLC | $873.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $623.11 | 2020-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $526.57 | 2019-2024 | |
| Abbott Laboratories | $516.82 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.56 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $479.81 | 2019-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $418.61 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $388.30 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $380.49 | 2021-2024 | |
| Amneal Pharmaceuticals LLC | $368.58 | 2019-2025 | Unithroid |
| Senseonics, Incorporated | $303.00 | 2019 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $281.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $150.06 | 2019-2020 | |
| Insulet Corporation | $144.82 | 2019-2024 | Omnipod |
| Mannkind Corporation | $133.58 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $104.07 | 2021-2024 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $103.38 | 2019-2024 | Strensiq |
| Amarin Pharma, INC. | $97.62 | 2020-2021 | |
| Dexcom, INC. | $84.19 | 2019-2021 | |
| Medtronic Minimed, INC. | $80.66 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $70.04 | 2023-2025 | Yorvipath |
| Beta Bionics, INC. | $65.62 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Horizon Therapeutics Plc | $58.31 | 2021-2023 | Tepezza |
| Eusa Pharma (US) LLC | $48.87 | 2022 | |
| Nevro Corp. | $46.14 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $38.18 | 2021-2022 | |
| Shire North American Group INC | $38.08 | 2019 | |
| Becton, Dickinson and Company | $32.54 | 2020-2022 | |
| Amryt Pharma Holdings LTD | $30.79 | 2022-2023 | Mycapssa |
| Madrigal Pharmaceuticals | $22.73 | 2025 | Rezdiffra |
| Vivus LLC | $22.61 | 2023 | Pancreaze |
| Companion Medical, INC. | $22.50 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $22.32 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.23 | 2023 | |
| Alvogen INC | $20.23 | 2023 | Teriparatide |
| Pfizer INC. | $18.99 | 2023 | |
| Cequr Corporation | $16.90 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.40 | 2020 | |
| Tolmar, INC. | $15.12 | 2024 | |
| Medtronic, INC. | $15.11 | 2023 | Minimed 780g |
| Ibsa Pharma INC. | $15.06 | 2021 | |
| Esperion Therapeutics, INC. | $13.82 | 2020 | |
| Acella Pharmaceuticals, LLC | $13.78 | 2025 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.